Introduction
Sjögren's syndrome (SS) is a relatively common autoimmune rheumatic disease, which is most common in women in the fifth decade of life. 1 According to a Brazilian population study, the prevalence of primary SS is 0.17%. 2 SS can occur in association with other autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in variable rates, up to 22.2% in patients with RA. 3, 4 SS is a slowly progressive chronic disease, characterized by a lymphocytic infiltrate that affects the epithelium of exocrine (mainly salivary and tear) glands, leading to a decreased production of tears and saliva. This is a systemic disease with high risk of transformation to lymphoma that primarily affects the joints, lungs, central nervous system (CNS), peripheral nervous system (PNS) and kidneys in approximately 50% of patients. 5 More recent studies have shown that there are subgroups of patients with different clinical manifestations, histological patterns (presence of germinative centers), cytokine profile and prognosis. 6, 7 In the near future, better genetic [8] [9] [10] and phenotypic characterization will be able to determine different treatment patterns. But nowadays it is possible to define treatment strategies based on symptoms (symptomatic treatment), and on the type and severity of systemic manifestations. These guidelines recommend the use of EULAR Sjö-gren's Syndrome Disease Activity (ESSDAI), a tool validated both internationally 11 and in Brazil, 12 as criteria for disease activity and response to treatment.
These recommendations were developed in order to guide the management and facilitate the access to treatment for those patients with an appropriate indication, considering the Brazilian socioeconomic context and pharmacological agents available in the country. Due to the length of this review, specific topics such as management during pregnancy and treatment of lymphoma associated with SS were not addressed. The recommendations were based on studies on primary Sjögren's syndrome. Considering the lack of studies in patients with association with other autoimmune diseases, these recommendations can be extrapolated to secondary Sjö-gren's syndrome.
Materials and methods
Articles were reviewed in MEDLINE (PubMed) and the Cochrane databases until December 2013. The manual update was held in October 2014. The search strategy was based on structured questions according to PICO (i.e. "Patient", "Intervention", "Controls" and "Outcome") format. These descriptors were used for cross-searching in accordance with the theme proposed in each of PICO questions. For all PICOs, the filter "random" was used, limiting the search to controlled studies. Studies published from January to October 2014 and some case series on extraglandular manifestations were manually included. After analyzing titles and abstracts, 131 articles related to questions that generated the evidence that provided the basis for these guidelines were selected (Fig. 1) . The studies Some recommendations were based solely on the opinion of experts from the Sjögren's Syndrome Scientific Committee of the Brazilian Society of Rheumatology (BSR), in the absence of studies on subjects. These recommendations were also graded as a D level and are not preceded by the reference.
PICOs were structured by a multidisciplinary team that was comprised of nine rheumatologists, members of the Sjögren's Syndrome Scientific Committee of BSR, with eight professionals from different areas (dentists, ophthalmologists, pathologists and physiotherapists); all were members of the Expanded Study Group on Sjögren's Syndrome (Grupo Ampliado de Estudos em Síndrome de Sjögren -GAESS -Brazil). The recommendations were formulated mainly based on evidence and reviewed by all participants at two meetings and several rounds of communication via the Internet, from April 2013 until October 2014.
Recommendations
Based on those 14 PICOs used in this survey, we organized didactically 16 questions with 44 recommendations, divided into three major topics and summarized in Figs 
Q2. Exercise is effective in treating patients with SS?
6. Women with SS have a lower physical ability, 13 and the practice of aerobic exercise at moderate to high intensity leads to the improvement of aerobic capacity, fatigue, perceived exertion and depression. 14 (B)
Q3. What are the effectiveness and safety of vaccines in patients with SS?
7. It is recommended that general guidelines for vaccination in patients with autoimmune diseases are followed 15 (C), and the vaccination status of the patient must be checked at the patient baseline assessment. It is also recommended SS patients should be encouraged to drink fluids frequently, preferably water. SS patients should be informed that tobacco, caffeine and various medications such as diuretics, beta blockers, antidepressants and anxiolytics, are known causes of dryness and can worsen the glandular symptoms. To prevent tear evaporation, the patient must avoid dry environments, air conditioning, wind, and also activities that decrease eye blinking, such as using the computer or reading for a long period of time. Patients with symptomatic dry eye should use environment humidifiers, and glasses with side shields during exposure to wind or when practicing outdoor sports. Preventive measures for oral health aim to control biofilm, caries, loss of teeth and oral candidiasis. For this purpose, it is important to maintain a good oral hygiene, keeping intraoral pH (basic) with the use of buffers and restricting consumption of sugar. Careful oral hygiene includes the same recommendations for the general population, with special attention to prosthesis hygiene and choosing less abrasive products, avoiding products that increase dryness of the mucosa, for example, toothpastes containing sodium lauryl sulfate and the use of alcohol-containing mouth rinse. Removable total dental prosthesis users should daily cleaned their dentures using a dental brush with stiff bristles with toothpaste, switching to a soft bristles brush for oral mucosa cleaning. Once a week, the prosthesis must be immersed in an aqueous solution containing 1% sodium hypochlorite solution during 30 min; then the prosthesis should be rinsed in running water.
One can obtain this concentration of sodium hypochlorite by diluting a tablespoon of chlorine bleach in a glass containing 300 mL of filtered water. 
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